Daebong LS (CEO: Park Jin-oh) announced on the 10th that it achieved consolidated sales of 29.1 billion won for Q1 2026, marking the highest quarterly performance in its history. This follows a landmark year in which the company first surpassed annual sales of 100 billion won, continuing the momentum of robust growth this year.
On a separate reporting basis, the company reported a revenue of 22.8 billion won, an 18% increase compared to the same period last year. The surge in sales is attributed to the rising demand for high-functionality bio-materials and customized formulation materials in the expanding global K-beauty market, thus solidifying Daebong LS's strategic positioning in key sectors.
Notably, overseas exports jumped 37% year-over-year, contributing significantly to the overall growth. Clean beauty materials tailored to climate conditions are experiencing ongoing demand in Southeast Asian markets like Indonesia and Vietnam, with increasing exports of hair care and advanced skincare materials. In the U.S. market, functional materials for sebum care are being supplied at an expanded scale, while in Europe, next-generation bio-materials based on PDRN are yielding visible results, reinforcing the company’s position in these territories.
The medical beauty segment, identified as a new growth driver, is entering a significant expansion phase. Recent entry of the adhesive transparent dressing "DB Jino Algi Bio Cell Cream MD" into major Health & Beauty retail platforms positions the company for rapid revenue increase, with plans to extend supply chains into pharmaceutical and hospital channels in the future.
Despite temporary declines in operating profit and net profit due to geopolitical risks affecting oil prices and currency volatility, as well as increased interest and depreciation costs stemming from the new headquarters in Songdo, Daebong LS expects to see a gradual recovery in profitability. The high value addition of global export products and efficiencies gained from the Songdo R&D center are anticipated to enhance profit margins. The anticipated increase in K-beauty demand at domestic duty-free shops and department stores, fueled by the influx of visiting tourists from Korea, further underlines potential for growth in key client supply.
Its subsidiary, P&K Skin Clinical Research Center, also contributed to consolidated growth, surpassing 6 billion won in revenue for two consecutive years due to rising demand for human application testing amidst the global K-beauty expansion. The company is also expanding its business portfolio through advancements in AI-driven beauty technology.
A representative from Daebong LS commented, "As we align with the growth of the global beauty industry, our competitive edge in high-functionality bio-materials is strengthening in overseas markets. We expect to see improvements in both profitability and growth as productivity enhancements and results from the development of high-value bio-materials, including peptides, begin to manifest in the second half of the year. Additionally, we plan to bolster growth momentum to encompass both bio and pharmaceutical sectors based on visible outcomes such as technology transfers for improved antifungal medications."
